BCR and chronic myelogenous leukemia, BCR-ABL1 positive: Previous work has shown that AURKA inhibition can improve the efficacy of agents such as bortezomib and the BCR::ABL1 inhibitor asciminib, with asciminib plus LY3295668 significantly increasing cytotoxicity in CML cells [36].